Drug interaction potential of resveratrol

Abstract

Resveratrol is a naturally occurring polyphenol that is often used as a food supplement. Many positive health effects, including cardio protection, tumor suppression, and immune modulation, are associated with the intake of resveratrol. Resveratrol is well tolerated in healthy subjects without any comedication. However, supplemental doses of resveratrol in the range of 1 g/day or above by far exceed the natural intake through food. Whether resveratrol-drug interactions can be harmful in patients taking additional medications remains unknown. Recent in vivo studies and clinical trials indicate a possible drug-drug interaction potential using high-dosage formulations. In this review, the known in vitro and in vivo effects of resveratrol on various cytochrome P450 (CYP) isoenzymes are summarized. They are discussed in relation to clinically relevant plasma concentrations in humans. We conclude that resveratrol may lead to interactions with various CYPs, especially when taken in high doses. Aside from systemic CYP inhibition, intestinal interactions must also be considered. They can potentially lead to reduced first-pass metabolism, resulting in higher systemic exposure to certain coadministrated CYP substrates. Therefore, patients who ingest high doses of this food supplement combined with additional medications may be at risk of experiencing clinically relevant drug-drug interactions.

Keywords::

• Resveratrol
• drug-drug interactions
• drug metabolism
• cytochrome P450

Acknowledgments

The continuous support of Dr. Paul Beilstein (DSM Ltd) is acknowledged. The authors thank Mark Inglin for proofreading of the manuscript for this article.

Declaration of interest

P.D. is supported by a public grant for a Ph.D. thesis project awarded by the Senglet Foundation (Basel, Switzerland). The company DSM markets resveratrol as a food supplement under the trade name Resvida^®. M.B. is an employee of DSM Nutritional Products Ltd.